HIG Ventures

We have detected that you do not have scripting allowed or the latest version of Macromedia Flash Player.

In order to display the content, please allow scripting or download and install the latest version now.

It will only take a moment. Click here to download Flash Player


	H.I.G. Ventures partners with entrepreneurs to provide the capital, expertise and relationships necessary to build market-leading businesses. With over $550 million in dedicated venture capital under management, the firm’s team invests nationally in early to growth-stage information technology, life sciences and service businesses... more ›


	Investment Spotlight Novadaq meets Key Commercialization Milestone with 50th SPY System.

Novadaq| Learn More


	Oct. 1, 2008: Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI) read more Sep. 4, 2008: Quinnova Pharmaceuticals, Inc. Announces Appointment of Senior Vice President of Research and Development read more Aug. 6, 2008: Quinnova Pharmaceuticals, Inc. Launches Cleanse and Treat read more Jun. 17, 2008: Tranzyme Pharma Announced Completion of a Phase I Trial read more May 19, 2008: Fairchild Semiconductor and Zilker Labs Enter Into a Partnership read more Apr. 7, 2008: Michael Gutch, Ph.D. Joins H.I.G. Ventures Life Sciences Team read more Jan. 31, 2008: Batanga Acquires HispanoClick read more Jan. 11, 2008: Alder Biopharmaceuticals, Inc. Completes $40M Series C Financing read more

H.I.G. is a leading global private investment firm with over $7.5 billion of capital under management. H.I.G.’s family of investment funds includes: